Aegis downgraded shares of Cynosure, Inc. (NASDAQ:CYNO) from a buy rating to a hold rating in a report issued on Wednesday.

Other research analysts also recently issued research reports about the stock. Northland Securities reiterated an outperform rating and issued a $60.00 price objective on shares of Cynosure in a research report on Thursday, February 16th. Zacks Investment Research upgraded shares of Cynosure from a strong sell rating to a hold rating in a research report on Wednesday, December 21st. Maxim Group downgraded shares of Cynosure from a buy rating to a hold rating and set a $66.00 price objective for the company. in a research report on Tuesday, February 14th. TheStreet upgraded shares of Cynosure from a hold rating to a buy rating in a research report on Wednesday, January 4th. Finally, Northcoast Research upgraded shares of Cynosure from a sell rating to a neutral rating in a research report on Tuesday, February 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. Cynosure has an average rating of Hold and an average price target of $57.88.

Analyst Recommendations for Cynosure (NASDAQ:CYNO)

Cynosure (NASDAQ:CYNO) opened at 66.00 on Wednesday. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of 110.00 and a beta of 1.65. The company has a 50-day moving average price of $61.02 and a 200 day moving average price of $50.59. Cynosure has a 52-week low of $38.93 and a 52-week high of $66.65.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/cynosure-inc-cyno-downgraded-by-aegis-to-hold.html

Cynosure (NASDAQ:CYNO) last issued its quarterly earnings data on Tuesday, February 7th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The business earned $122.10 million during the quarter, compared to the consensus estimate of $119.97 million. Cynosure had a net margin of 3.56% and a return on equity of 6.86%. The company’s revenue was up 19.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.42 earnings per share. On average, analysts expect that Cynosure will post $1.56 earnings per share for the current year.

Your IP Address:

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fortaleza Asset Management Inc. increased its position in Cynosure by 58.1% in the fourth quarter. Fortaleza Asset Management Inc. now owns 3,795 shares of the company’s stock valued at $173,000 after buying an additional 1,395 shares during the period. Thrivent Financial for Lutherans increased its position in Cynosure by 6.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 12,860 shares of the company’s stock valued at $586,000 after buying an additional 800 shares during the period. Teachers Retirement System of The State of Kentucky increased its position in Cynosure by 0.6% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 33,768 shares of the company’s stock valued at $1,540,000 after buying an additional 200 shares during the period. Boothbay Fund Management LLC bought a new position in Cynosure during the fourth quarter valued at $253,000. Finally, Guggenheim Capital LLC increased its position in Cynosure by 7.1% in the fourth quarter. Guggenheim Capital LLC now owns 38,475 shares of the company’s stock valued at $1,755,000 after buying an additional 2,538 shares during the period.

Cynosure Company Profile

Cynosure, Inc develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health.

5 Day Chart for NASDAQ:CYNO

Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.